Formulation, Characterization, and Stability of Protein Drugs: Case Histories: Pharmaceutical Biotechnology, cartea 9
Editat de Rodney Pearlman, Y. John Wangen Limba Engleză Hardback – 31 oct 1996
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1377.02 lei 6-8 săpt. | |
Springer Us – 6 mai 2013 | 1377.02 lei 6-8 săpt. | |
Hardback (1) | 1384.66 lei 6-8 săpt. | |
Springer Us – 31 oct 1996 | 1384.66 lei 6-8 săpt. |
Preț: 1384.66 lei
Preț vechi: 1457.54 lei
-5% Nou
Puncte Express: 2077
Preț estimativ în valută:
265.01€ • 279.57$ • 220.84£
265.01€ • 279.57$ • 220.84£
Carte tipărită la comandă
Livrare economică 03-17 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780306453328
ISBN-10: 0306453320
Pagini: 432
Ilustrații: XXVIII, 432 p.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.81 kg
Ediția:2002
Editura: Springer Us
Colecția Springer
Seria Pharmaceutical Biotechnology
Locul publicării:New York, NY, United States
ISBN-10: 0306453320
Pagini: 432
Ilustrații: XXVIII, 432 p.
Dimensiuni: 155 x 235 x 30 mm
Greutate: 0.81 kg
Ediția:2002
Editura: Springer Us
Colecția Springer
Seria Pharmaceutical Biotechnology
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
A Compendium and Hydropathy/ Flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gin, and Met Motifs in Neutral pH Solution.- Characterization, Stability, and Formulations of Basic Fibroblast Growth Factor.- The Characterization, Stabilization, and Formulation of Acidic Fibroblast Growth Factor.- Stability, Characterization, Formulation, and Delivery System Development for Transforming Growth Factor-Beta1.- Stability and Characterization of Recombinant Human Relaxin.- Interferon-?-1b (Betaseron®): A Model for Hydrophobic Therapeutic Proteins.- Characterization, Formulation, and Stability of Neupogen® (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor.- Development and Shelf-Life Determination of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (LEUKINE®, GM-CSF).- Formulation Development of an Antifibrin Monoclonal Antibody Radiopharmaceutical.- Biophysical Characterization and Formulation of TP40: A Chimeric Protein that Requires a pH-Dependent Conformational Change for Its Biological Activity.- Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme®, (Dornase Alpha)].